Daewoong Pharmaceutical Co., Ltd (KRX:069620)

Market Cap	1.99T
Revenue (ttm)	1.54T
Net Income (ttm)	93.19B
Shares Out	11.51M
EPS (ttm)	8,098.18
PE Ratio	21.31
Forward PE	11.82
Dividend	600.00 (0.35%)
Ex-Dividend Date	Dec 29, 2025

Volume	41,112
Average Volume	42,698
Open	172,800
Previous Close	173,100
Day's Range	168,200 - 175,900
52-Week Range	109,000 - 199,400
Beta	0.06
RSI	48.59
Earnings Date	Feb 9, 2026

About Daewoong Pharmaceutical

Daewoong Pharmaceutical Co., Ltd. develops, manufactures and commercializes pharmaceutical products in South Korea and internationally. It offers products in therapeutic areas, such as central nervous system, endocrinology, musculoskeletal, nephrology, antineoplastic, cardiovascular, gastrointestinal, metabolic, antiviral, analgesic, antacid, and digestive diseases, as well as wound, iron supplements, and muti-vitamins. The company also provides COVID-19 PCR kit, COVID-19 IgG/IgM RDT, and viral transport medium medical devices. The company was ...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 1945
• Employees: 1,644
• Stock Exchange: Korea Stock Exchange
• Ticker Symbol: 069620

Financial Performance

In 2024, Daewoong Pharmaceutical's revenue was 1.42 trillion, an increase of 3.44% compared to the previous year's 1.38 trillion. Earnings were 24.73 billion, a decrease of -79.68%.